MINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.159
EU - Europa 18.101
AS - Asia 14.010
SA - Sud America 2.303
OC - Oceania 301
AF - Africa 297
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 61.178
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.888
RU - Federazione Russa 6.981
SG - Singapore 4.097
PL - Polonia 3.856
CN - Cina 3.658
HK - Hong Kong 2.273
BR - Brasile 1.886
IE - Irlanda 1.847
KR - Corea 1.707
IT - Italia 1.658
SE - Svezia 1.092
VN - Vietnam 780
DE - Germania 700
FI - Finlandia 556
IN - India 508
UA - Ucraina 455
GB - Regno Unito 335
AU - Australia 291
JO - Giordania 247
FR - Francia 183
AR - Argentina 178
ID - Indonesia 149
CA - Canada 131
TR - Turchia 112
JP - Giappone 97
MX - Messico 86
CH - Svizzera 85
EC - Ecuador 84
ES - Italia 80
ZA - Sudafrica 77
BD - Bangladesh 75
IQ - Iraq 66
CI - Costa d'Avorio 62
NL - Olanda 62
AT - Austria 55
BE - Belgio 49
CO - Colombia 40
MA - Marocco 39
VE - Venezuela 30
BJ - Benin 26
CL - Cile 25
PK - Pakistan 25
PE - Perù 22
PY - Paraguay 22
TH - Thailandia 22
SA - Arabia Saudita 21
EG - Egitto 18
UZ - Uzbekistan 18
AE - Emirati Arabi Uniti 17
LT - Lituania 17
SC - Seychelles 15
CZ - Repubblica Ceca 14
PH - Filippine 14
NP - Nepal 13
UY - Uruguay 13
MY - Malesia 12
TN - Tunisia 12
AL - Albania 11
IL - Israele 11
IR - Iran 11
KE - Kenya 11
AZ - Azerbaigian 10
DO - Repubblica Dominicana 10
DZ - Algeria 10
NZ - Nuova Zelanda 10
TW - Taiwan 10
JM - Giamaica 9
KZ - Kazakistan 9
GR - Grecia 8
LB - Libano 8
OM - Oman 7
DK - Danimarca 6
HN - Honduras 6
RS - Serbia 6
TT - Trinidad e Tobago 6
BG - Bulgaria 5
CR - Costa Rica 5
ET - Etiopia 5
PA - Panama 5
PT - Portogallo 5
SY - Repubblica araba siriana 5
BY - Bielorussia 4
EU - Europa 4
GE - Georgia 4
LV - Lettonia 4
MK - Macedonia 4
NO - Norvegia 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
BB - Barbados 3
BO - Bolivia 3
CY - Cipro 3
MD - Moldavia 3
MU - Mauritius 3
NG - Nigeria 3
RO - Romania 3
SN - Senegal 3
SV - El Salvador 3
BT - Bhutan 2
Totale 61.134
Salva come PNG Salva come JPEG
Città #
Santa Clara 5.980
Warsaw 3.828
Singapore 2.853
Ashburn 2.254
Fairfield 2.104
Dublin 1.838
Hong Kong 1.829
Seoul 1.655
Chandler 1.603
Hefei 1.369
Woodbridge 970
Cambridge 868
Seattle 864
Houston 797
Wilmington 758
Jacksonville 680
Beijing 630
San Jose 609
Ann Arbor 453
Buffalo 422
Los Angeles 397
Princeton 382
Altamura 366
Lawrence 357
Florence 323
Moscow 302
Boston 296
The Dalles 292
Melbourne 285
Dallas 281
Mumbai 279
Ho Chi Minh City 267
Helsinki 230
Boardman 206
Munich 194
Kent 190
Shanghai 182
New York 164
Medford 163
São Paulo 161
Hanoi 145
San Diego 126
Clifton 104
Tokyo 89
Bremen 88
Paris 87
Jakarta 84
West Jordan 78
Redondo Beach 77
Bern 75
Bengaluru 74
Falls Church 74
Turku 73
Milan 64
Abidjan 62
Norwalk 61
Rio de Janeiro 61
Dearborn 60
Rome 58
Toronto 57
Dong Ket 56
London 55
Phoenix 54
Pune 53
Izmir 51
Belo Horizonte 46
Hillsboro 46
Brussels 44
Vienna 44
Council Bluffs 41
Guangzhou 40
Johannesburg 40
Chicago 38
Chennai 36
Da Nang 36
Barcelona 35
Frankfurt am Main 35
Auburn Hills 32
Denver 31
Yubileyny 31
Brooklyn 30
Tianjin 29
Montreal 28
Guayaquil 27
Haiphong 27
Cotonou 26
Andover 25
Curitiba 25
Baghdad 24
Poplar 24
Atlanta 23
Goiânia 22
Porto Alegre 22
Quito 22
San Francisco 22
Orem 21
Stockholm 21
Brasília 20
Elk Grove Village 20
Biên Hòa 19
Totale 40.599
Salva come PNG Salva come JPEG
Nome #
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 356
Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy 349
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 349
Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents. 334
Solution Chemistry and Cytotoxic Properties of Novel Organogold(III) Compounds 333
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 331
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 330
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 321
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 318
Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor 317
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. 314
Emerging drugs in refractory colorectal cancer 314
Natural compounds for cancer treatment and prevention 310
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 308
The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents. 307
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 305
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 301
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 298
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 295
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 295
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment 294
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 289
Druggable Targets in Pancreatic Adenocarcinoma 286
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. 274
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 266
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 264
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 252
Mutations of the APC gene in human sporadic colorectal cancers. 237
[Medical therapy of malignant melanoma] 229
Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer 228
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 228
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 221
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight 217
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 216
Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters 214
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 209
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. 207
Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. 203
N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent Pgp-dependent multidrug resistance (MDR) inhibitors 201
Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm) 198
Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. 197
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 196
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. 194
Cellular pharmacology of gemcitabine. 194
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 193
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 191
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. 191
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 189
Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids 187
New structure–activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR) 185
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 184
A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. 183
Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). 182
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 182
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 180
Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs) 175
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 175
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 175
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 175
Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 174
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 173
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 173
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 172
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study 172
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. 172
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 170
LIPOSOMES LOADED WITH BERBERINE HYDROCHLORIDE: DEVELOPMENT, OPTIMISATION AND IN VITRO CITOTOXICITY 170
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 169
Pharmacogenetics: Implementing personalized medicine 168
Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. 166
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin 164
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 162
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 162
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now? 161
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 160
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 160
Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity 160
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 160
Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations 159
Inflammation in Urological Malignancies: The Silent Killer 158
Chromosomal characterization of methotrexate-resistant human T-lymphoblast leukemia cells (CCRF-CEM) with impaired polyglutamylation. 158
Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 157
The clinical role of PIK3CA mutations in colorectal cancer 156
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. 156
Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin 155
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study 155
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 155
Germline mutations in MSH2 and ATM gene in patients with GIST (gastrointestinal stromal tumor) and second epitelial tumors 155
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 154
Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues. 154
Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review 153
1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis 153
Role of Non-Coding RNAs in Colorectal Cancer: Focus on Long Non-Coding RNAs 152
5-methyltetrahydrofolate (mTHF) induces monocytes differentiation in HL60 cells 152
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study 151
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 151
Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat. 151
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. 151
6106 POSTER Immune-boost Treatment With Gemcitabine, Oxaliplatin, Levofolinate, 5-flurouracil, Granulocyte/macrophage Colony-stimulating-factor (GM-CSF) and Aldesleukine Enhances Progression-free and Overall-survival Over FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients – Early Results From the GOLFIG-2 Phase III Trial 151
Adverse effects of macrolide antibacterials. 150
Totale 21.201
Salva come PNG Salva come JPEG
Categoria #
all - tutte 175.219
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 175.219
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.869 0 0 0 0 0 0 193 288 349 525 219 295
2021/20222.368 70 224 104 99 78 160 85 212 144 102 403 687
2022/20237.370 607 1.087 244 652 631 1.473 976 451 837 51 174 187
2023/20243.071 137 286 537 118 195 449 174 664 67 185 137 122
2024/202518.969 804 2.152 1.154 2.844 5.115 2.425 278 774 1.096 481 821 1.025
2025/202615.766 2.588 3.610 2.842 2.734 2.235 776 981 0 0 0 0 0
Totale 61.786